Introduction
Apoptosis plays an essential role in the homeostasis of multicellular organisms. [1] [2] [3] Aberrations of this process are deleterious to the organism: excessive apoptosis causes damage to normal tissues in certain autoimmune disorders, whereas a failure of apoptosis allows cells to grow unchecked, resulting in cancers. A wide variety of apoptosis-inducing molecules have been identified. Among apoptosis-inducing proteins, the best characterized are ligand-type cytokine molecules of the tumor necrosis factor (TNF) family. TNF family member proteins, such as TNF-a, FasL and TNF-related apoptosis-inducing ligand (TRAIL), are type II transmembrane molecules, in which the carboxyl-terminus of the receptor-binding domain protrudes extracellularly. These molecules trigger the apoptotic signal cascades through binding cognate receptors displayed on the cell surface. [4] [5] [6] Activated TNF-R1 recruits a cellular adaptor protein TRADD. 7 TRADD sequentially recruits other cellular proteins such as FADD 8 and TNF receptor-associated factor 2 (TRAF2). FADD directly interacts with procaspase-8 and initiates the apoptotic signaling pathways. TRAF2 stimulates the signal pathways leading to the activation of NF-kB that results in inhibition of apoptosis in some cell types. 9, 10 Thus, TNF-R stimulation activates both pro-and antiapoptotic signaling pathways simultaneously. Activation of Fas and TRAIL-Rs primarily recruits FADD as a cellular adaptor molecule. [11] [12] [13] [14] As a result, Fas and TRAIL-Rs predominantly activate the apoptotic signaling pathways. Once activated, caspase-8 initiates intracellular signaling cascades of proteolytic events and leads to the cleavage of cytosolic, cytoskeletal and nuclear proteins as well as DNA.
Although TRAIL is a member of the TNF family, TRAIL has some notable differences from other members. Unlike Fas, TRAIL receptors are widely expressed. 15, 16 This feature allows most tissues and cell types to become TRAIL targets. More importantly, TRAIL has a strong selectivity for induction of tumor cell apoptosis in vitro as well as in vivo. 17, 18 Hence, in contrast to FasL or agonistic Fas antibody that induces fulminant massive liver damage in systemic delivery, 19, 20 TRAIL exhibits no detectable cytotoxicity in murine 18 and primate models. 17 These features have drawn considerable attention to TRAIL as a potential therapy for human cancers.
Recent crystal structure analyses have demonstrated that soluble TRAIL (amino acids 114-281) containing the receptor-binding domain forms a homotrimer, [21] [22] [23] and that this homotrimeric structure is required for the apoptotic function of TRAIL. Trimeric TRAIL is stabilized by a zinc ion that is positioned in a pocket generated by three TRAIL molecules. 22, 23 This zinc ion interacts with a unique cysteine residue in TRAIL. Hence, removal of the zinc ion from trimeric TRAIL or a change of the cysteine residue to other amino acids results in a loss of apoptotic function of TRAIL. 22, 23 In addition to stabilizing the trimeric structure of TRAIL, the zinc ion prevents oxidation of the cysteine residue. Oxidation between cysteine residues forms a homodimeric TRAIL. 24 As we and others demonstrated recently, 24, 25 the dimeric TRAIL has much lower apoptotic activity than trimeric TRAIL. These data indicate that trimerization is critical for proper TRAIL function.
Based on these structural features of TRAIL, we recently created an artificial TRAIL gene that encodes a fusion protein composed of three functional elements: 26 a secretion signal, a trimerization domain and an apoptosis-inducing moiety of the TRAIL gene sequence. Delivery of this gene into cultured cells caused expression and secretion of trimeric TRAIL into the culture supernatant. This secreted trimeric TRAIL showed greater apoptotic activity than the known TRAIL protein that does not contain an additional trimerization domain.
Gene therapy has several advantages over conventional drug therapies. First, high dose and long-term expression of a drug can be achieved relatively easily. Second, the drug may be delivered locally and specifically to target tissues. This reduces the risk of ineffective dosing and nonspecific toxicity that is seen with systemic administration. In an attempt to establish a TRAIL-based cancer gene therapy, we developed an adenoviral vector delivering the gene that encodes our secretable trimeric TRAIL (stTRAIL). This adenovirus (Ad-stTRAIL) potently suppressed tumor cell growth in vitro and in vivo by inducing apoptotic cell death. Expression of stTRAIL by Ad-stTRAIL tumor tissues persisted for more than 4 days, while systemically delivered recombinant TRAIL is rapidly cleared from the blood circulation. Although several studies have shown that Ad-flTRAIL delivering the full-length TRAIL gene effectively suppresses tumor growth in vivo, 27, 28 Ad-stTRAIL showed higher tumor suppressor activity than that of AdflTRAIL in evaluation of tumor suppressor activity after mixing infected cells with uninfected cells and implanting these mixed cells to the nude mice. Our data implicate Ad-stTRAIL as a potential therapeutic to treat human cancers.
Results

Induction of cell death by Ad-stTRAIL in different cell lines
Full-length TRAIL is expressed as a transmembrane protein whose receptor-binding domain protrudes extracellularly. The structure analysis by crystallography has demonstrated that the receptor-binding domaincontaining soluble TRAIL (amino acids 114-281), prepared after deleting the transmembrane domain, is a homotrimer. [21] [22] [23] This homotrimeric structure has been shown to be essential for the apoptotic function of TRAIL. 21, 22 In an attempt to establish a cancer gene therapy using the TRAIL gene, we previously examined whether the TRAIL gene segment containing the receptor-binding domain (amino acids 114-281) produces functional TRAIL in mammalian cells. 26 Although this TRAIL gene segment expressed functional TRAIL in bacterial cells, it produced only inactive TRAIL protein in 293T cells. 26 However, an addition of a trimerization-enforcing domain (ILZ, isoleucine zipper) to the N-terminus converted this inactive TRAIL to the functional TRAIL, named ILZ-TRAIL. Our data indicate that unlike bacterial cells overexpressing target recombinant proteins, mammalian cells require an effective means for homotrimerizing TRAIL.
In general, secreted proteins have better target access than nonsecreted proteins. Particularly, ligand molecules like TRAIL, which act by binding to the receptors displayed on the cell surface, may have better effects when secreted into the circulation or culture supernatant. Indeed, a secretion signal fused to the N-terminus of ILZ-TRAIL effectively secreted ILZ-TRAIL to the culture supernatant and increased its apoptotic activity. 26 However, the secretion signal turned out not to be directly involved in TRAIL-induced apoptosis. To avoid a potential undesirable immune response in a therapeutic application, we eliminated the secretion signal from SS-ILZ-TRAIL by utilizing a specific protease cleavage sequence, which is recognized by Furin, 29 a protease mainly residing in Golgi complex. This Furin-specific cleavage sequence added to the C-terminus of the secretion signal (Figure 1a ) cleaved off the secretion signal during the secretion process of SS-ILZ-TRAIL. Final secreted product ILZ-TRAIL showed potent apoptotic activity. 26 In this subsequent study, therefore, we establish a TRAIL-based gene therapy using our artificial gene encoding stTRAIL polypeptide composed of SS-ILZ-TRAIL (Figure 1a) .
For effective cancer gene therapy, overexpression of the delivered transgenes is critical. Adenovirus is known to deliver the transgenes most effectively and has been widely used in clinical applications. The 293 cells, commonly used for the preparation of adenoviral vectors, tolerated stTRAIL well in the amplification process of Ad-stTRAIL. Thus, we selected adenovirus as a delivery vector for stTRAIL.
We prepared a replication-incompetent adenovirus (Ad-stTRAIL) and first examined its cell death-inducing activity using various cell lines, such as HeLa (cervix), MDA-MB-231 (breast), A549 (lung), HCT116 (colon) and U-87MG (brain). We infected these cell lines with AdstTRAIL (MOI 50) for 3 days and analyzed cell viability (Figure 1b) . The control adenovirus Ad-c5 did not decrease cell viability (data not shown). In contrast, Ad-stTRAIL effectively decreased cell viability in all the tested cell lines. Ad-stTRAIL-induced cell death was completely inhibited by a pancaspase inhibitor z-VAD-fmk (data not shown), indicating that AdstTRAIL induces cell death mainly through apoptosis. Our data indicate that Ad-stTRAIL effectively delivers the stTRAIL gene and has a therapeutic potential for different cancers originated from a broad range of tissues.
In vitro tumor suppressor activity of Ad-stTRAIL Malignant gliomas of astrocytic origin, including astrocytoma, anaplastic astrocytoma and glioblastoma, are the most common primary brain tumors in humans. 30, 31 The last three decades have seen intensive research on these tumors; however, patient survival has not been significantly improved. It is therefore tempting to test therapeutic efficacy of Ad-stTRAIL in these tumors. We selected a human glioma cell line U-87MG for further studies of Ad-stTRAIL, although Ad-stTRAIL showed a therapeutic potential for various cancers originating from different tissues.
We first determined the dose versus cytotoxic effects of Ad-stTRAIL in vitro. We infected U-87MG cells with either Ad-stTRAIL or control virus Ad-c5, and analyzed cell viability by MTS assay after a 3-day incubation. As a positive control, we used different doses (1-80 ng/ml) of recombinant human TRAIL (rhTRAIL) protein. Both AdstTRAIL and rhTRAIL effectively decreased cell viability in a dose-dependent manner, while Ad-c5 did not show any cytotoxic effects regardless of doses ( Figure 2a ). Unlike low doses of rhTRAIL, even at an MOI of 1, AdstTRAIL showed detectable cytotoxic effects. To determine whether or not cytotoxicity of Ad-stTRAIL is due to apoptosis, we conducted flow cytometric analysis using Annexin V-FITC. Compared with the control group infected with Ad-c5 (Figure 2b ), the Ad-stTRAIL-treated group showed an increased number of apoptotic cells in a dose-dependent manner. The rhTRAIL-treated group, a positive control, also showed increased apoptosis in a dose-dependent manner. These results indicate that AdstTRAIL decreases cell viability by inducing apoptosis.
We observed that Ad-stTRAIL-induced cell death is completely inhibited by a pancaspase inhibitor z-VADfmk or a caspase-8 inhibitor z-IETD-fmk (data not shown). A soluble TRAIL receptor DR5 also effectively inhibited cell death induced by Ad-stTRAIL (data not shown). These results clearly indicate that Ad-stTRAIL induces cell death by secreting expressed stTRAIL into the culture supernatant. We next measured the levels of stTRAIL protein, secreted into the culture supernatant, by ELISA after infecting cells with different doses of AdstTRAIL for 3 days (Figure 2c ). TRAIL protein in culture supernatant was undetectable in Ad-c5-infected cells. By contrast, Ad-stTRAIL-infected cells secreted stTRAIL protein into the culture supernatant in a dose-dependent manner (Figure 2c ). At an MOI of 100, the levels of secreted stTRAIL dramatically increased, reaching approximately 3000 pg/ml. Our data indicate that AdstTRAIL expresses and secretes stTRAIL from the infected U-87MG cells and effectively induces apoptotic cell death.
In vivo tumor suppressor activity of Ad-stTRAIL
To assess tumor suppressor activity and adverse effects of Ad-stTRAIL in vivo, we first established a tumor model in mice by injecting 1 Â 10 6 U-87MG cells subcutaneously onto the left flank region of SCID mice. When the tumor diameter reached 2-3 mm, we then delivered Hanks' balanced salt solution (HBS), Ad-c5 (1 Â 10 9 PFU), Ad-stTRAIL (1 Â 10 9 PFU) or rhTRAIL (3 mg) intratumorally to the tumor-bearing mice. Two vehicle control groups (HBS injected or Ad-c5 injected) did not show detectable difference in tumor growth ( Figure 3 ). Compared to these control gropus, AdstTRAIL or rhTRAIL showed potent tumor suppressor activity (Po0.05) (Figure 3 ). Ad-stTRAIL was observed to have even stronger tumor suppressor activity than the rhTRAIL that has demonstrated antitumor activity in a number of studies. It is noteworthy that one of the five tumor-bearing animals became tumor-free at the end of the experiments. Injection of Ad-stTRAIL or rhTRAIL neither induces undesirable cell death in adjacent normal tissues nor causes observable changes in food and water consumption, body weight, movement or behavior (data not shown), suggesting that Ad-stTRAIL is as safe as the known rhTRAIL in vivo. Our data indicate that Ad-stTRAIL effectively suppresses tumor growth without detectable adverse effects. 
Expression of stTRAIL by Ad-stTRAIL in tumor tissues
To determine whether in vivo antitumor activity of AdstTRAIL directly correlates with the levels of stTRAIL expressed in tumor tissues, we measured the protein levels of stTRAIL after injecting the vehicle controls (HBS or Ad-c5) or Ad-stTRAIL into the tumor tissues ( Figure 4 ). On different days (day 1, 3, 4 and 5) following injection of the vehicle controls or Ad-stTRAIL, we collected tumor tissues and analyzed expressed stTRAIL by ELISA. In the vehicle control groups, soluble TRAIL protein was undetectable throughout the experimental period ( Figure 4 and data not shown). In contrast, Ad-stTRAIL produced stTRAIL that was detectable on day 3, peaked on day 4 and decreased on day 5 ( Figure 4) .
When measuring the levels of TRAIL protein produced by the control vehicles or Ad-stTRAIL in tumor tissues, we focused on only human TRAIL by using a monoclonal antibody for human TRAIL as a capture antibody in ELISA. However, we do not rule out the possibility that the control vehicles or Ad-stTRAIL activate mouse TRAIL production by stimulating an immune response in the host organism, which might result in antitumor effects observed for Ad-stTRAIL. To examine this possibility, we established an ELISA using a monoclonal antibody for mouse TRAIL as a capture antibody and analyzed the protein levels of mouse TRAIL protein on different days (day 1, 3, 4 and 5) following injection of vehicle controls or Ad-stTRAIL into tumor tissues. Contrary to human TRAIL ELISA, we were unable to detect any changes in the expression levels of mouse TRAIL protein in tumor tissues (data not shown). Our data indicate that delivery of Ad-stTRAIL effectively expresses stTRAIL protein in tumor tissues and in vivo tumor suppressor activity of Ad-stTRAIL is governed by stTRAIL, not by endogenous host TRAIL. (Figure 5a ), indicating that a high degree of apoptotic cell death occurred in the AdstTRAIL-injected group. In agreement with these H&E staining results, delivery of Ad-stTRAIL resulted in substantially increased TUNEL-positive staining ( Figure  5b ). Our data clearly indicate that Ad-stTRAIL suppresses tumor growth by inducing tumor cell apoptosis.
Histological analysis of in vivo
Ad-stTRAIL-treated tumor tissues We examined whether in vivo delivery of Ad-stTRAIL into tumor tissues induces tumor cell death via apoptosis. To address this question, we injected the vehicle controls (HBS or Ad-c5) or Ad-stTRAIL into the tumor tissues, excised the tumor tissues 3 days later and performed histological analysis. The H&E staining results revealed that Ad-stTRAIL significantly increased the number of the cells with condensed nuclei, but the vehicle controls did not
Comparison of tumor suppressor activity between Ad-stTRAIL and Ad-flTRAIL
Previous studies have demonstrated that when delivered intratumorally, an adenovirus conveying the full-length TRAIL gene (Ad-flTRAIL) also effectively suppresses tumor growth in vivo without significant side effects. 27, 28 Thus, it is tempting to compare tumor suppressor activity between Ad-stTRAIL and Ad-flTRAIL. Since the main difference between Ad-stTRAIL and AdflTRAIL is capability of secretion, we assessed how effectively Ad-stTRAIL or Ad-flTRAIL kills surrounding tumor cells in vivo.
We infected U-87MG cells with Ad-c5, Ad-stTRAIL or Ad-flTRAIL at an MOI of 100 for 2 h, extensively washed the cells and mixed these infected cells with uninfected U-87MG cells (the ratio of infected cells to uninfected cells is 1:4). We then implanted these mixed cells on the left flank of SCID mice and assessed their tumor suppressor activity by measuring the tumor sizes from day 5 to day 26 ( Figure 6a ). Although Ad-c5 dose not deliver any cytotoxic genes, Ad-c5-infected tumors gradually regressed for the first 7 days; however, on day 15, Ad-c5-infected tumors resumed their growth and kept growing for the entire period of the experiments. In contrast, Ad-flTRAIL and Ad-stTRAIL effectively suppressed tumor growth. Notably, while Ad-flTRAIL-infected tumors were always palpable for the entire period of the experiments, Ad-stTRAILinfected tumors completely regressed by day 14.
Since TRAIL potently activates caspases, we examined whether tumor regression is associated with the activation of caspases. We collected tumor tissues from the mice on day 7 and analyzed caspase-3 activation employing two different methods: fluorometric measure- (Figure 6b ). Ad-flTRAIL was also observed to increase caspase-3 activity, although the increase is not significant. In contrast, AdstTRAIL dramatically increased caspase-3 activity. In Western blotting analysis, a less sensitive detection method than the fluorometric measurement, cleaved caspase-3 was detectable only in Ad-stTRAIL-infected tumor tissues (Figure 6c ). Our data clearly indicate that Ad-stTRAIL has higher tumor suppressor activity than that of Ad-flTRAIL, and that secretion of active soluble TRAIL provides a better means for limiting tumor growth.
Discussion
Studies have demonstrated that TRAIL has a cancerspecific killer activity without damaging normal cells and tissues in vivo. 17, 18 Although the mechanism for this cancer-selective action of TRAIL is poorly understood, it is widely agreed that TRAIL has a potential to become a promising anticancer therapy.
Here, we demonstrated that Ad-stTRAIL is an effective apoptosis inducer in vitro and in vivo. AdstTRAIL induced apoptotic cell death in cancer cell lines derived from various tissues (cervix, breast, lung, colon and brain) (Figure 1 ), revealing a therapeutic potential for different cancers. Like the known recombinant TRAIL protein, Ad-stTRAIL did not show detectable adverse side effects in in vivo feasibility tests. Interestingly, AdstTRAIL showed detectable apoptotic activity even at an MOI of 1 in in vitro assays using a U-87MG human glioma cell line, although a significant amount of stTRAIL protein was not detected at this viral dose (Figure 2 ). Our data also demonstrated that in contrast to the recombinant TRAIL protein, which is rapidly cleared Figure 6 Comparison of tumor suppressor activity between AdstTRAIL and Ad-flTRAIL in vivo. After implanting mixed U-87MG cells to SCID mice (n ¼ 9 for each group), tumor sizes were measured (a). On day 7, mice (n ¼ 3 for each group) were killed and tumors were processed and subjected to measurement of caspase-3 activity (RFU, relative fluorescence units) (b) or Western blotting for examining caspase-3 cleavage (c). 
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from the blood circulation when administered systemically, expression of stTRAIL by Ad-stTRAIL in tumor tissues persisted for more than 4 days (Figure 4) .
In a comparison of tumor suppressor activity between Ad-stTRAIL and Ad-flTRAIL, Ad-stTRAIL showed higher tumor suppressor activity than that of AdflTRAIL ( Figure 6 ). Analysis of caspase-3 activity and activation in tumor tissues revealed that Ad-stTRAIL maintains caspase-3 activation for a longer time than AdflTRAIL. Our data suggest that flTRAIL, which is not readily secreted, rapidly kills only infected cells and adjacent tumor cells, whereas stTRAIL is diffused throughout tumor tissues and kills tumor cells in more widespread areas. These unique features enable AdstTRAIL to act as a potent tumor suppressor in vivo (Figures 3 and 6) . Our data clearly indicate that, like the tested recombinant TRAIL protein, Ad-stTRAIL has a potential to become a potent, safe and cancer-selective anticancer therapy.
Our previous report 26 has demonstrated that stTRAIL (ILZ-TRAIL(114-281)) ( Figure 1a ) induces tumor cell death in vitro by activating the known TRAIL-triggered signaling pathways and there is no apparent difference in activation signaling compared to that activated by recombinant TRAIL protein (TRAIL(114-281)). These results suggest that the ILZ moiety stabilizes TRAIL structure but is not directly involved in TRAIL-activated death signaling. In agreement with these results, stTRAIL induces cell death in vivo mainly via apoptosis ( Figure 5 ). Although stTRAIL turned out to be safe in vivo in this study, the effects of this added ILZ moiety on host immune response remain to be determined. Recently, we successfully purified ILZ-TRAIL(114-281) from bacterial cells. Using this ILZ-TRAIL protein, we are now characterizing the significance of the ILZ in apoptotic function and in vivo host immune response against this moiety. These further studies will lessen the concern of using Ad-stTRAIL for clinical applications.
Although Ad-stTRAIL showed a therapeutic potential for different cancers, here we evaluated therapeutic efficacy and adverse side effects in vivo using a glioma model. Unlike most of other malignancies, malignant gliomas are localized. 32 This feature facilitates in vivo feasibility tests of a gene therapy approach mainly designed for intratumoral application. A local administration of Ad-stTRAIL will easily achieve an effective dose of stTRAIL. Since Ad-stTRAIL is designed to secrete stTRAIL, local secretion of stTRAIL will lead to active apoptosis induction in uninfected neighboring tumor cells.
Malignant gliomas score high mortality; however, the current treatments for these tumors, including surgery, chemotherapy and radiotherapy, do not substantially improve the high mortality rate. 33 In general, the most effective therapy for malignancies is a curative surgery, mainly comprising a wide resection. However, unlike other malignancies, a wide resection of tumor tissues in malignant gliomas is highly limited, since this wide resection might result in an unwanted loss of brain function. The cytoreductive surgery, therefore, might leave a certain amount of tumor mass in the primary site. Thus, in addition to the individual therapy comprising Ad-stTRAIL alone, it will be worth evaluating the combination therapies comprising Ad-stTRAIL and surgery (also possibly with other therapies such as chemotherapy and radiation therapy) for their efficacy and adverse side effects. 34 Currently, using more glioma cell lines, we are evaluating therapeutic efficacy of AdstTRAIL individual therapy as well as various combination therapies in vitro and in vivo.
Although we showed potent tumor suppressor activity of Ad-stTRAIL in this study, further studies using a glioma model, in which tumors are implanted into the brain rather than the skin, may be needed for better evaluation of efficacy and adverse side effects of AdsTRAIL. We are now establishing an animal glioma model by implanting U-87MG cells intracranially to the SCID mice. In this animal model, we will not only assess efficacy and adverse side effects but also determine the effective infectious titers of Ad-stTRAIL and the optimal number of injection times. The data gathered from these studies will be valuable for determining clinical application of Ad-stTRAIL in humans.
One of the most notable advantages of the adenoviral vector over other vectors is high efficiency of the transgene delivery, which is especially critical for effective cancer gene therapy. 35, 36 The production of high-titer infectious adenoviral vectors in a small volume is also achieved relatively easily. These features allow adenoviral vectors to easily deliver a maximal dose of the transgene to target tissues, including localized gilomas. 32, 37 Even though there is concern about a host immune response against adenovirus, recent phase I clinical trials are promising for the use of adenoviral vectors. Clinical data reveal that patients tolerate the treatment well and that the transgenes effectively express even in the presence of pre-existing immunity to adenovirus. 38 These results suggest that controlled doses of Ad-stTRAIL can be applied repeatedly. We are now investigating the relationship between repeated administration of Ad-stTRAIL and the expression levels of stTRAIL in tumor tissues and the blood circulation.
Our data clearly demonstrate the potential of AdstTRAIL in anticancer therapy. Our further studies will assess applicability of Ad-stTRAIL as a therapeutic drug for the treatment of human cancers. Our stTRAIL-based gene therapy approach will provide fresh insights into cancer gene therapy.
Materials and methods
Reagents rhTRAIL was obtained from R&D systems (Minneapolis, MN, USA). Antibodies against human TRAIL, biotinylated human TRAIL, mouse TRAIL, biotinylated mouse TRAIL and avidin-horseradish peroxidase (HRP) conjugate were purchased from PeproTech (Rocky Hill, NJ, USA), PeproTech, R&D systems, R&D systems and BD Bioscience (San Diego, CA, USA), respectively. An E1-and E3-deleted replication-incompetent adenoviral vectors Ad-stTRAIL and Ad-flTRAIL were constructed through Cre-lox recombination as described. 39 Briefly, the stTRAIL gene cassette, 26 or full-length TRAIL cDNA driven by the CMV promoter and terminated by the bovine growth hormone poly-A signal was inserted into the shuttle vector pAdlox to create pAdlox-stTRAIL or pAdlox-flTRAIL. Ad-stTRAIL and Ad-flTRAIL were generated by cotransfection of appropriately digested pAdlox-stTRAIL or pAdlox-flTRAIL with C5 helper virus DNA into the adenovirus packaging cell line CRE8 that expresses Cre recombinase. Ad-stTRAIL and Ad-flTRAIL propagated on 293 cells were purified by cesium chloride density-gradient centrifugation and subsequent dialysis against a Tris-saline (50 mM Tris (pH 7.5), 200 mM NaCl and 3% sucrose) and kept at À801C until use.
Adenoviral infection
HeLa, MDA-MB-231, A549, HCT116 or U-87MG cells, plated into 12 wells (2 Â 10 5 cells/well) in complete medium, were infected with the adenoviral vector (Adc5 as a vector control or Ad-stTRAIL) at different titers (MOI 1, 10, 50 or 100). At 3 days after incubation, cells were harvested and processed for the analysis of cell viability.
Apoptosis assays
Cells infected with adenoviral vectors or treated with rhTRAIL as a positive control were analyzed for apoptosis using the MTS assay kit purchased from Promega (Madison, WI, USA) or by flow cytometry using Annexin V-FITC obtained from Oncogene (San Diego, CA, USA).
ELISA for expressed stTRAIL stTRAIL protein secreted into the culture supernatants were analyzed by ELISA following two-fold dilution with an incubation buffer (2% BSA, 0.5% Tween-20 in PBS). For the analysis of stTRAIL expressed in tumor tissues, tumor tissues were lysed in a buffer (25 mM TrisCl (pH 7.4), 50 mM NaCl, 0.5% Na-deoxycholate, 2% Nonidet P-40, 0.2% SDS and 10% protease inhibitor cocktail (Sigma)), diluted four-folds with the incubation buffer and subjected to ELISA. The plates (Immuno Maxisorp) purchased from Nalge Nunc (Rochester, NY, USA) were prepared by coating with anti-human TRAIL antibody (1.5 mg/ml) in a binding solution (50 ml/well, 0.1 M Na 2 HPO 4 (pH 9.0)) and by blocking with a blocking solution (200 ml/well, 2% BSA in PBS). The plates were then incubated with culture supernatants, tumor tissue lysates or rhTRAIL as a standard. After 1 h incubation at 371C, the plates were washed and treated with diluted biotinylated anti-human TRAIL antibody (100 ml/well, 0.2 mg/ml in incubation buffer) for 1 h at room temperature. Following washing, diluted avidin-HRP (100 ml/ well, 1/1000 dilution) was added and incubated for 30 min at room temperature. ABTS solution (Sigma) was added for color development and measured by reading absorbance at 405 nm.
Animal experiments
To generate an animal tumor model, 6-week-old male B6.CB17 SCID mice purchased from the Jackson Laboratory (Bar Harbor, ME, USA) were subcutaneously injected with 1 Â 10 6 U-87MG cells on the left frank region. When the diameter of tumors reached 2-3 mm, the tumors were injected with HBS, Ad-c5 (1 Â 10 9 PFU) or Ad-stTRAIL (1 Â 10 9 PFU). As a positive control, rhTRAIL was administrated at 3 mg/tumor. Tumor volumes were calculated by using the formula A Â B 2 Â 0.5, where A and B represent the larger and smaller diameter of tumor, respectively.
To compare tumor suppressor activity between AdstTRAIL and Ad-flTRAIL in vivo, 5 Â 10 5 U-87MG cells harvested by trypsinization were infected with Ad-c5, Ad-stTRAIL or Ad-flTRAIL at an MOI of 100 for 2 h at 371C washed with PBS three times, mixed with 2 Â 10 6 control U-87MG cells, implanted onto the left flank of SCID mice (n ¼ 9 for each group) followed by tumor size measurement for 26 days. For measuring caspase-3 activity or examining caspase-3 cleavage, tumors were harvested from the three mice in each group (a 'no virus' group was added as a background control) on day 7, lysed in a buffer (25 mM Tris-Cl (pH 7.4), 50 mM NaCl, 0.5% Na-deoxycholate, 2% NP-40, 0.2% SDS and 10% protease inhibitor cocktail (Sigma)) and subjected to fluorometric analysis of caspase-3 activity (Calbiochem, La Jolla, CA, USA) or Western blotting for caspase-3 cleavage in which human-specific caspase-3 antibody was used to distinguish human caspase-3 delivered by Ad-stTRAIL or Ad-flTRAIL from mouse tissue TRAIL.
All the procedures for animal experiments were approved by the Institutional Animal Care and Use Committee of Dong-A Pharmaceutical Co., Ltd.
TUNEL staining and histology
At 3 days after intratumoral injection of HBS, Ad-c5 or Ad-stTRAIL, mice were killed and cryostat sections were prepared. Cryostat sections (16 mm) were air-dried and stained with H&E, or subjected to TUNEL staining. TUNEL staining was carried out using the kit DeadEnd Fluorometric TUNEL system from Promega (Madison, WI, USA).
Statistical analyses
Analysis of differences was performed using the Wilcoxon's rank-sum test.
